Reviva Pharmaceuticals Holdings, Inc. (RVPH)
After hours:
| Previous close | 2.8000 |
| Open | 2.8300 |
| Bid | 2.7900 x 100 |
| Ask | 2.8700 x 300 |
| Day's range | 2.8000 - 3.1800 |
| 52-week range | 2.6700 - 8.6100 |
| Volume | |
| Avg. volume | 254,378 |
| Market cap | 78.73M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the
- GlobeNewswire
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024 - CUPERTINO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies
- GlobeNewswire
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024; topline data expected Q2 2025 – – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Most non-clinical activities completed and preparation is underway to support a New Drug Application (NDA) submission fo
